100 Clinical Results associated with Apollo Therapeutics Group Ltd.
0  Patents (Medical) associated with Apollo Therapeutics Group Ltd.
01 May 2024·C108. MECHANISMS OF LUNG INFLAMMATION AND INFECTION
A Rhinovirus VP0 Vaccine Induces Cross-reactive Type 1 Immunity and Promotes Lymphocyte Activation and Maturation
Author: Shaw, S.  ; Edwards, M.R.  ; Johnston, S.L.  ; Patel, N.D.  ; Pyle, C.J. 
01 May 2023·D13. INNATE AND ADAPTIVE IMMUNE MECHANISMS REGULATING LUNG DISEASE
A Rhinovirus-A16 VP0 Vaccine Induces Homotypic Humoral and Cellular Immunity, and Following Heterotypic Rhinovirus-A01 Infection, Accelerates Virus Clearance and Induces Cross-strain IFN-γ T Cell and Neutralising Antibody Responses
Author: Shaw, S.  ; Edwards, M.R.  ; Wang, Z.  ; Patel, N.D.  ; Tregoning, J.S.  ; Hamblin, P.  ; Johnston, S.L.  ; Pyle, C.J.  ; Butt, R. 
100 Deals associated with Apollo Therapeutics Group Ltd.
100 Translational Medicine associated with Apollo Therapeutics Group Ltd.